神经药理学报

神经药理学报 ›› 2024, Vol. 14 ›› Issue (1): 18-.DOI: 10.3969/j.issn.2095-1396.2024.01.003

• 研究论文 • 上一篇    下一篇

保妇康栓联合重组人干扰素α-2b 治疗高危HPV感染的疗效和安全性观察

陈莹，尤继文，林艳，陈云香   

  1. 1. 福建省福安市妇幼保健院孕产保健科，福安，355000，中国 

    2. 福建省福安市妇幼保健院妇保科，福安，355000，中国 

    3. 福建省福安市医院中医科，福安，355000，中国

  • 出版日期:2024-02-26 发布日期:2024-05-24
  • 作者简介:陈莹，主治医师；研究方向：妇产科方向；E-mail：chenying20231109@163.com

Observation on the Efficacy and Safety of Baofukang Suppository Combined with Recombinant Human Interferon α-2b in the Treatment of High-Risk HPV Infection

CHEN Ying, YOU Ji-wen, LIN Yan, CHEN Yun-xiang   

  1. 1. Department of Maternal Health Care, Fuan Maternal and Child Health Hospital, Fuan, 355000, China 

    2. Department of Obstetrics and Gynecology, Fuan Maternal and Child Health Hospital of Fujian Province, Fuan, 355000, China 

    3. Department of Traditional Chinese Medicine, Fuan Hospital of Fujian Province, Fuan, 355000, China

  • Online:2024-02-26 Published:2024-05-24
  • About author:陈莹，主治医师；研究方向：妇产科方向；E-mail：chenying20231109@163.com

PDF (PC)

69

摘要：

目的：探讨高危型人乳头瘤病毒（high-risk human papillomavirus, HR-HPV） 感染在重组人干扰素α-2b基 础上加用保妇康栓的治疗效果和安全性。方法：HR-HPV患者80例随机分为两组，对照组（40例）予以重组人干扰素 α-2b阴道泡腾胶囊治疗，观察组（40例）在使用重组人干扰素α-2b阴道泡腾胶囊基础上予以保妇康栓治疗，两组 均治疗3个月。对比两组治疗效果，记录两组异常分泌物持续时间、HPV病毒载量、薄层液基细胞学检查（thinprep cytologic test， TCT）检测结果和宫颈炎症积分，并观察不良反应。结果：与对照组（75.00%）进行比较，观察组总有效 率（95.00%）更高（P<0.05）。观察组异常分泌物持续时间为（14.47±3.15） d，与对照组的（20.12±3.89） d相比显著缩短 (P<0.05)。治疗后，两组TCT正常率相比治疗前显著增高（P<0.05），且相比对照组，观察组TCT正常率更高（P<0.05）。 治疗后，观察组相比对照组，HPV病毒载量下降（P<0.05），宫颈炎症积分降低（P<0.05）。不良反应发生率在两组之间 比较未显示出统计学差异（P>0.05）。结论：保妇康栓治疗HR-HPV感染患者予以重组人干扰素α-2b联合保妇康栓 治疗有着显著疗效，且安全性好。

关键词: 人乳头瘤病毒, 重组人干扰素α-2b, 保妇康栓, 疗效

Abstract:

Objective：To investigate the efficacy and safety of Baofukang suppository on the basis of recombinant human interferon α-2b in the treatment of high-risk human papillomavirus (HR-HPV) infection. Methods： 80 HR-HPV patients were randomly divided into 2 groups. The control group (40 cases) was treated with recombinant human interferon α-2b vaginal effervescent capsule. The observation group (40 cases) was treated with Baofukang suppository on the basis of recombinant human interferon α-2b vaginal effervescent capsule. Both groups were treated for 3 months. The treatment effects of the two groups were compared.The duration of abnormal secretions, HPV viral load, TCT test results and cervical inflammation scores of the two groups were recorded, and the adverse reactions were observed. Results： Compared with the control group (75.00%), the total effective rate of the observation group (95.00%) was higher (P<0.05). The duration of abnormal secretions in the observation group was (14.47±3.15) d, comparing with the control group (20.12±3.89) d, shows significantly shorter (P<0.05). After treatment, the normal rate of TCT in the two groups was significantly higher than that before treatment (P<0.05 ), and the normal rate of TCT in the observation group was higher than that in the control group(P<0.05). After treatment, the HPV viral load in the observation group decreased comparing with the control group (P<0.05), and the cervical inflammation score decreased (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion： Baofukang suppository based on recombinant human interferon α-2b vaginal effervescent capsule is effective and safe in the treatment of HRHPV infection.

Key words: human papillomavirus, recombinant human interferon α-2b, baofukang suppository, curative effect